A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively.
Health insurance provider Elevance Health (NYSE:EVH) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 13.4% year on year to $49.78 billion. Its non-GAAP profit of $8.84 per share was 1.4% below analysts’ consensus estimates.
Health insurance provider Elevance Health (NYSE:EVH) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 13.4% year on year to $49.78 billion. Its non-GAAP profit of $8.84 per share was 1.4% below analysts’ consensus estimates.
Shares of health insurance provider Elevance Health (NYSE:EVH)
fell 11.5% in the afternoon session after the company reported its second-quarter results and cut its full-year profit guidance, citing rising medical costs. The health insurer announced second-quarter adjusted earnings of $8.84 per share, which missed Wall Street's expectation of $9.16 per share. While revenue of $49.42 billion beat forecasts, the company's net income declined to $1.74 billion from $2.30 billion in the same quarter last year. The key concern for investors was the significant reduction in the company's full-year 2025 profit outlook. Elevance now expects adjusted earnings per share of approximately $30.00, a substantial cut from its previous forecast of $34.15 to $34.85. Management attributed the downgrade to "elevated medical cost trends" in its Medicaid and Affordable Care Act (ACA) health plans. This was reflected in a higher benefit expense ratio—the percentage of premiums spent on medical care—which rose to 88.9%, indicating that costs are growing faster than premiums. The news also weighed on shares of other health insurers facing similar cost pressures.
A number of stocks fell in the morning session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
Shares of health insurance provider Elevance Health (NYSE:EVH)
fell 9.9% in the afternoon session after peer, Centene pulled its full-year financial guidance, triggering a sector-wide sell-off.
The company reaffirmed its full-year adjusted core profit guidance and noted that oncology cost trends remained below forecast through the first two-thirds of the quarter.
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names.
But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.
Healthcare solutions company Evolent Health (NYSE:EVH) reported Q1 CY2025 results exceeding the market’s revenue expectations, but sales fell by 24.4% year on year to $483.6 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $455 million was less impressive, coming in 9.4% below expectations. Its non-GAAP profit of $0.06 per share was 33% below analysts’ consensus estimates.
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts.
But that doesn’t mean the underlying businesses are cheap, and we advise caution as many have questionable fundamentals.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025.
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the healthcare technology for providers industry, including Evolent Health (NYSE:EVH) and its peers.
A number of stocks fell in the afternoon session after the major indices pulled back (Nasdaq -1.3%, S&P 500 - 1.4%) as Treasury yields rose, reflecting market anxiety over a draft federal budget that could worsen the already wide US fiscal deficit.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 6.7%. This performance was disappointing since the S&P 500 held its ground.
Healthcare solutions company Evolent Health (NYSE:EVH) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 24.4% year on year to $483.6 million. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $455 million was less impressive, coming in 9.4% below expectations. Its non-GAAP profit of $0.06 per share was 37.7% below analysts’ consensus estimates.
Healthcare solutions company Evolent Health (NYSE:EVH)
will be announcing earnings results tomorrow after market close. Here’s what investors should know.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Evolent Health (NYSE:EVH) and the rest of the healthcare technology for providers stocks fared in Q4.
